ANALGESIC USE AND THE RISK OF CHRONIC RENAL FAILURE
镇痛药的使用和慢性肾功能衰竭的风险
基本信息
- 批准号:2634316
- 负责人:
- 金额:$ 51.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-08-15 至 2003-07-31
- 项目状态:已结题
- 来源:
- 关键词:acetaminophen analgesics aspirin blood chemistry chronic renal failure clearance rate clinical research creatinine cryopreservation disease /disorder proneness /risk dosage drug administration rate /duration drug adverse effect female health surveys human data human subject human tissue iatrogenic disease longitudinal human study nonsteroidal antiinflammatory agent nurses outcomes research questionnaires statistics /biometry urinalysis
项目摘要
DESCRIPTION: Analgesic-associated nephropathy is potentially fatal and
costly yet completely preventable as a cause of renal dysfunction.
Retrospective studies have reported an increased risk of renal dysfunction
associated with consumption of large amounts of acetaminophen and
nonsteroidal anti-inflammatory drugs (NSAIDs) but not aspirin. Since these
analgesics are widely available and used, their association with renal
dysfunction is particularly important. The primary objective of this study
is to examine, prospectively, the association between chronic consumption of
acetaminophen, aspirin and NSAIDs, and the risk of chronic renal
dysfunction, defined as an increase in serum creatinine or a decrease in
calculated creatinine clearance during the 5-year study period. From
participants in two large female cohorts, the Nurses' Health Studies I and
II (NHSI, NHSII), 3 groups of women will be identified, each comprised of
1150 participants (half from each cohort), who reported frequent use of
acetaminophen, aspirin, or NSAIDs, and a fourth group of 1150 women who
reported no use of these analgesics. Detailed information on dosage and
duration of analgesic use will be obtained through supplementary
questionnaires, to be mailed in the 01, 03, and 05 years, which have been
shown to be reproducible. 4600 nurses will be enrolled at the outset and,
after excluding women with prevalent renal disease and those who drop out,
an expected 4000 will complete the study in the 05 year. The outcomes are:
change in serum creatinine and calculated creatine clearance, measured at
baseline and years 03 and 05 from all subjects. Mixed effects regression
will be used to analyze the slope of renal function in the unexposed and
exposed groups during the 5 year study period. For approximately 2000
subjects in NHSI, stored blood from 1989 will be used to perform the same
analyses over a 13 year period. This study will provide: prospective data
on change in renal function associated with chronic analgesic use; threshold
levels of safe cumulative dose and duration of these analgesics; and
population-based incidence rates and attributable risks of
analgesic-associated chronic renal dysfunction.
描述:止痛剂相关的肾病具有潜在的致命性
成本高昂,但完全可以预防,因为这是导致肾功能障碍的一个原因。
回顾研究报告了肾功能不全的风险增加。
与大量服用扑热息痛和
非类固醇抗炎药(NSAIDs),但不是阿司匹林。因为这些
止痛药被广泛获得和使用,它们与肾脏的关系
功能障碍尤其重要。这项研究的主要目的是
就是前瞻性地研究长期消费与
扑热息痛、阿司匹林和非甾体抗炎药与慢性肾脏风险
功能障碍,定义为血清肌酐增加或
计算5年研究期内的内生肌酐清除量。从…
两个大型女性队列的参与者,护士健康研究I和
将确定三组妇女,每组包括
1150名参与者(每组一半),他们报告经常使用
扑热息痛、阿司匹林或非甾体抗炎药,以及第四组1150名女性
报告说没有使用过这些止痛药。剂量和剂量的详细信息
止痛药的使用时间将通过补充获得
在01年、03年和05年邮寄的问卷,已经
被证明是可复制的。开始时将招收4600名护士,
在排除了患有常见肾脏疾病的女性和辍学的女性之后,
预计将有4000人在05年内完成这项研究。结果是:
血清肌酐的变化和计算的肌酸清除量,在
所有受试者的基线和03和05年。混合效应回归
将被用来分析非接触者肾功能的斜率
暴露组在5年的研究期间。大约2000年
在国家卫生研究院的受试者中,储存的血液将用于执行相同的操作
历时13年的分析。这项研究将提供:前瞻性数据
慢性使用止痛药对肾功能影响的研究
这些止痛药的安全累积剂量和持续时间;以及
基于人群的发病率和可归因性风险
止痛药相关的慢性肾功能障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY C. CURHAN其他文献
GARY C. CURHAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY C. CURHAN', 18)}}的其他基金
Sex-related differences in incidence rates of nephrolithiasis
肾结石发病率的性别相关差异
- 批准号:
9178999 - 财政年份:2011
- 资助金额:
$ 51.83万 - 项目类别:
Factors influencing change in 24 hour urine composition
影响24小时尿液成分变化的因素
- 批准号:
8663895 - 财政年份:2011
- 资助金额:
$ 51.83万 - 项目类别:
Factors influencing change in 24 hour urine composition
影响24小时尿液成分变化的因素
- 批准号:
8086955 - 财政年份:2011
- 资助金额:
$ 51.83万 - 项目类别:
Factors influencing change in 24 hour urine composition
影响24小时尿液成分变化的因素
- 批准号:
8242057 - 财政年份:2011
- 资助金额:
$ 51.83万 - 项目类别:
Factors influencing change in 24 hour urine composition
影响24小时尿液成分变化的因素
- 批准号:
8464086 - 财政年份:2011
- 资助金额:
$ 51.83万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 51.83万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 51.83万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 51.83万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 51.83万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 51.83万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 51.83万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 51.83万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 51.83万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 51.83万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 51.83万 - 项目类别:














{{item.name}}会员




